drugset / Trial / NCT05899829
Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 1, 2-part, open-label, fixed-sequence study evaluating the effect of rifampin (part 1) and rabeprazole (part 2) on the pharmacokinetics of a single dose of camlipixant (BLU-5937) 50 mg tablet in healthy participants under fasting conditions.
Timeline
- Start
- 2023-06-21
- Primary completion
- 2023-08-08
- Completion
- 2023-08-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camlipixant | Small molecule | 50 mg | Oral |
| Subject | Rabeprazole | Small molecule | 20 mg | Oral |
| Subject | Rifampin | Small molecule | 600 mg | Oral |
Indications
No indication recorded.